Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus PREDNISOLONE TEBUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus PREDNISOLONE TEBUTATE.
CORTONE vs PREDNISOLONE TEBUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
Corticosteroid that binds to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell activity.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
20-60 mg intramuscularly or intra-articularly once daily as a single dose or divided every 6-12 hours; dose varies by indication and severity.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Terminal half-life: 2-4 hours (plasma); clinical effects persist longer (18-36 hours) due to prolonged receptor occupancy and transcriptional effects.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Renal: primarily as metabolites, <20% unchanged; small fecal/biliary contribution.
Category C
Category D/X
Corticosteroid
Corticosteroid